Publications: Prof Thomas Powles
Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A et al.
(
2020
)
.
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors
.
The Journal of urology
vol.
204
,
(
6
)
1173
-
1179
.
Loveday C, Litchfield K, Proszek PZ, Cornish AJ, Santo F, Levy M, Macintyre G, Holryod A et al.
(
2020
)
.
Genomic landscape of platinum resistant and sensitive testicular cancers
.
Nature Communications
vol.
11
,
(
1
)
Necchi A, Nishiyama H, Matsubara N, Lee JL, Petrylak DP, de Wit R, Drakaki A, Liepa AM et al.
(
2020
)
.
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
.
BMC Urology
vol.
20
,
(
1
)
Albiges L, Tannir N, Burotto M, Mcdermott D, Plimack E, Barthélémy P, Porta C, Powles T et al.
(
2020
)
.
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés
.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
vol.
30
,
(
13
)
785
-
786
.
Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK et al.
(
2020
)
.
The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future
.
European Urology
vol.
78
,
(
5
)
731
-
742
.
Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA et al.
(
2020
)
.
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
.
The Lancet Oncology
vol.
21
,
(
10
)
1309
-
1316
.
Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE et al.
(
2020
)
.
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers
.
European urology oncology
vol.
3
,
(
5
)
671
-
679
.
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovi¿ S et al.
(
2020
)
.
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
.
New England Journal of Medicine
vol.
383
,
(
13
)
1218
-
1230
.
Grünwald V, Voss MH, Rini BI, Powles T, Albiges L, Giles RH, Jonasch E
(
2020
)
.
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
.
British Journal of Cancer
vol.
123
,
(
6
)
898
-
904
.
Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S et al.
(
2020
)
.
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy
.
European Urology Focus
vol.
6
,
(
5
)
999
-
1005
.
Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon J-C, Ficial M et al.
(
2020
)
.
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
.
Clin Cancer Res
Vuky J, Balar AV, Castellano D, O¿Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D et al.
(
2020
)
.
Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer
.
Journal of Clinical Oncology
vol.
38
,
(
23
)
2658
-
2666
.
Szabados B, Abu-Ghanem Y, Grant M, Choy J, Bex A, Powles T
(
2020
)
.
Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors
.
European Urology
vol.
78
,
(
2
)
276
-
280
.
Abu-Ghanem Y, Fernández-Pello S, Bex A, Ljungberg B, Albiges L, Dabestani S, Giles RH, Hofmann F et al.
(
2020
)
.
Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel
.
European urology oncology
vol.
3
,
(
4
)
433
-
452
.
Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER et al.
(
2020
)
.
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
.
Journal for ImmunoTherapy of Cancer
vol.
8
,
(
2
)
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al.
(
2020
)
.
Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
.
European Urology
vol.
78
,
(
1
)
e48
-
e50
.
Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW et al.
(
2020
)
.
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
.
BJU International
vol.
126
,
(
1
)
73
-
82
.
Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N et al.
(
2020
)
.
Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic[Formula presented]
.
European Urology
vol.
78
,
(
1
)
29
-
42
.
Lee LYW, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VWT et al.
(
2020
)
.
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study
.
The Lancet
vol.
395
,
(
10241
)
1919
-
1926
.
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al.
(
2020
)
.
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis
.
Journal of Clinical Oncology
vol.
38
,
(
18_suppl
)
lba1
-
lba1
.
Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, Carroll J, Fontes M et al.
(
2020
)
.
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
.
Proceedings of the National Academy of Sciences of the United States of America
vol.
117
,
(
22
)
12288
-
12294
.
Gillessen S, Powles T
(
2020
)
.
Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic
.
European Urology
vol.
77
,
(
6
)
667
-
668
.
Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Suarez C, Bracarda S, Stadler WM et al.
(
2020
)
.
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab þ Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
.
Clinical Cancer Research
vol.
26
,
(
11
)
2506
-
2514
.
Grivas P, Plimack ER, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn NM et al.
(
2020
)
.
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
.
European urology oncology
vol.
3
,
(
3
)
351
-
359
.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al.
(
2020
)
.
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)
.
Nature Medicine
vol.
26
,
(
6
)
Szabados B, Powles T
(
2020
)
.
Immune checkpoint inhibition in urothelial carcinoma
.
The Lancet
vol.
395
,
(
10236
)
1522
-
1523
.
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P et al.
(
2020
)
.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
.
Nature Medicine
vol.
26
,
(
5
)
693
-
698
.
Fulton B, Jones R, Powles T, Crabb S, Paul J, Birtle A, Chowdhury S, Hussain S et al.
(
2020
)
.
ATLANTIS: A randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer
.
Trials
vol.
21
,
(
1
)
Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A et al.
(
2020
)
.
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
.
The Lancet
vol.
395
,
(
10232
)
1268
-
1277
.
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al.
(
2020
)
.
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer[Formula presented]
.
European Urology
vol.
77
,
(
4
)
420
-
433
.
de Bruijn R, Wimalasingham A, Szabados B, Stewart GD, Welsh SJ, Kuusk T, Blank C, Haanen J et al.
(
2020
)
.
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data
.
European urology oncology
vol.
3
,
(
2
)
168
-
173
.
Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T et al.
(
2020
)
.
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
.
Annals of Oncology
vol.
31
,
(
4
)
525
-
531
.
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al.
(
2020
)
.
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5
.
European Urology
vol.
77
,
(
4
)
436
-
438
.
Al-Lamki RS, Hudson NJ, Bradley JR, Warren AY, Eisen T, Welsh SJ, Riddick ACP, O`Mahony FC et al.
(
2020
)
.
The efficacy of sunitinib treatment of renal cancer cells is associated with the Protein PHAX in vitro
.
Biology
vol.
9
,
(
4
)
Powles T
(
2020
)
.
Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer
.
European Urology
vol.
77
,
(
4
)
454
-
456
.
Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P et al.
(
2020
)
.
Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer[Formula presented]
.
European Urology
vol.
77
,
(
2
)
269
-
276
.
Witjes JA, Babjuk M, Bellmunt J, Maxim Bruins H, De Reijke TM, De Santis M, Gillessen S, James N et al.
(
2020
)
.
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort<sup>†</sup>[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees
.
European Urology
vol.
77
,
(
2
)
223
-
250
.
Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH et al.
(
2020
)
.
Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel
.
European urology oncology
vol.
3
,
(
1
)
57
-
72
.
Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T et al.
(
2020
)
.
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
.
European Journal of Cancer
vol.
126
,
1
-
10
.
Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, Hawkins R, Bracarda S et al.
(
2020
)
.
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
.
European Urology
Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA et al.
(
2020
)
.
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
.
Nature Medicine
Liu WK, Lam JM, Butters T, Grant M, Jackson-Spence F, Bex A, Powles T, Szabados B
(
2020
)
.
Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach
.
World Journal of Urology
Grant M, Szabados B, Kuusk T, Powles T, Bex A
(
2020
)
.
Cytoreductive nephrectomy: Does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything?
.
Current Opinion in Urology
vol.
30
,
(
1
)
36
-
40
.
Drakaki A, Kirby CJ, Van Der Heijden MS, Petrylak DP, Powles T, Chi KN, Fléchon A, Necchi A et al.
(
2020
)
.
Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
.
Bladder Cancer
vol.
6
,
(
1
)
43
-
52
.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH et al.
(
2020
)
.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
.
The Lancet Oncology
Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al.
(
2020
)
.
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival
.
Urologic Oncology: Seminars and Original Investigations
Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J
(
2020
)
.
Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy
.
European Urology
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA et al.
(
2020
)
.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
.
The Lancet Oncology
vol.
21
,
(
1
)
105
-
120
.
Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J
(
2020
)
.
Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.08.033
.
European Urology
Powles T, Walker J, Andrew Williams J, Bellmunt J
(
2020
)
.
The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
.
Cancer Treatment Reviews
vol.
82
,
Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G et al.
(
2019
)
.
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
.
BMC Cancer
.
vol.
19
,
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al.
(
2019
)
.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
.
Nature Medicine
vol.
25
,
(
11
)
1706
-
1714
.
Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al.
(
2019
)
.
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
.
Annals of Oncology
vol.
30
,
(
11
)
1697
-
1727
.
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S et al.
(
2019
)
.
Erratum: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (Annals of Oncology (2018) 29(2) (361–369), (S0923753419350392), (10.1093/annonc/mdx692))
.
Annals of Oncology
vol.
30
,
(
11
)
Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B et al.
(
2019
)
.
PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: Analysis of the randomized clinical trials Meteor and Cabosun
.
Clinical Cancer Research
vol.
25
,
(
20
)
6080
-
6088
.
Song D, Powles T, Shi L, Zhang L, Ingersoll MA, Lu YJ
(
2019
)
.
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
.
Journal of Pathology
vol.
249
,
(
2
)
151
-
165
.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B et al.
(
2019
)
.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
.
The Lancet Oncology
vol.
20
,
(
10
)
1370
-
1385
.
Szabados B, van Dijk N, Tang YZ, van der Heijden MS, Wimalasingham A, Gomez de Liano A, Chowdhury S, Hughes S et al.
(
2019
)
.
Re: Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer
.
Journal of Urology
vol.
202
,
(
4
)
658
-
659
.
De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L et al.
(
2019
)
.
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)(Figure presented.)
.
European Urology
vol.
76
,
(
4
)
437
-
440
.
Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U et al.
(
2019
)
.
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer
.
Oncologist
vol.
24
,
(
10
)
1348
-
1355
.
Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY et al.
(
2019
)
.
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer
.
Cancer
vol.
125
,
(
18
)
3155
-
3163
.
Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U et al.
(
2019
)
.
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
.
Oncologist
vol.
24
,
(
9
)
1151
-
e817
.
Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al.
(
2019
)
.
Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ (European Journal of Cancer (2019) 108 (33–40), (S0959804918315399), (10.1016/j.ejca.2018.11.031))
.
European Journal of Cancer
vol.
119
,
200
-
201
.
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al.
(
2019
)
.
Intensive Imaging-Based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-Recurrence Survival: Results from a European Multicentre Database (RECUR)
.
Journal of Urology
vol.
202
,
(
3
)
455
-
456
.
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al.
(
2019
)
.
Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis
.
European Urology Focus
vol.
5
,
(
5
)
857
-
866
.
Grimm MO, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J et al.
(
2019
)
.
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019
.
European Urology
vol.
76
,
(
3
)
368
-
380
.
Alifrangis C, McGovern U, Freeman A, Powles T, Linch M
(
2019
)
.
Molecular and histopathology directed therapy for advanced bladder cancer
.
Nature Reviews Urology
vol.
16
,
(
8
)
465
-
483
.
Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB et al.
(
2019
)
.
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
.
European Urology
vol.
76
,
(
2
)
151
-
156
.
Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M et al.
(
2019
)
.
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
.
Cancer Cell
vol.
36
,
(
1
)
35
-
50.e9
.
Neves JB, Shepherd S, Cullen D, Powles T, Aitchison M, Tran MGB
(
2019
)
.
Performance and cost of a renal cancer specialist multidisciplinary team meeting: Results from 1500 discussions
.
Journal of Clinical Urology
vol.
12
,
(
4
)
314
-
319
.
Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U et al.
(
2019
)
.
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract
.
European Urology
vol.
76
,
(
1
)
73
-
81
.
Porta C, Cosmai L, Leibovich BC, Powles T, Gallieni M, Bex A
(
2019
)
.
The adjuvant treatment of kidney cancer: a multidisciplinary outlook
.
Nature Reviews Nephrology
vol.
15
,
(
7
)
423
-
433
.
Rini BI, Powles T
(
2019
)
.
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply
.
The New England journal of medicine
vol.
380
,
(
26
)
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM et al.
(
2019
)
.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
.
The Lancet
vol.
393
,
(
10189
)
2404
-
2415
.
Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SFP, Giles RH, Hofmann F et al.
(
2019
)
.
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
.
European Urology
vol.
75
,
(
5
)
799
-
810
.
Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, Von Loga K et al.
(
2019
)
.
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
.
Journal for ImmunoTherapy of Cancer
vol.
7
,
(
1
)
Lam JM, Liu WK, Powles T, Tang YZ, Szabados B
(
2019
)
.
Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition
.
Eur Urol Oncol
Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M et al.
(
2019
)
.
Imaging in Suspected Renal-Cell Carcinoma: Systematic Review
.
Clinical Genitourinary Cancer
vol.
17
,
(
2
)
e345
-
e355
.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B et al.
(
2019
)
.
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
.
New England Journal of Medicine
vol.
380
,
(
12
)
1116
-
1127
.
Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al.
(
2019
)
.
Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023))
.
European Urology
vol.
75
,
(
3
)
e82
-
e83
.
Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A et al.
(
2019
)
.
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis
.
European Urology Focus
vol.
5
,
(
2
)
242
-
249
.
Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY et al.
(
2019
)
.
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale
.
Future Oncology
vol.
15
,
(
9
)
929
-
941
.
van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS
(
2019
)
.
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
.
European Urology
vol.
75
,
(
3
)
435
-
444
.
Bex A, Mulders P, Jewett M, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Del Pilar Laguna M et al.
(
2019
)
.
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
.
JAMA Oncology
vol.
5
,
(
2
)
164
-
170
.
Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al.
(
2019
)
.
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma
.
European Journal of Cancer
vol.
108
,
33
-
40
.
Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T et al.
(
2019
)
.
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer
.
World Journal of Urology
vol.
37
,
(
1
)
95
-
105
.
Kuusk T, Szabados B, Liu WK, Powles T, Bex A
(
2019
)
.
Cytoreductive nephrectomy in the current treatment algorithm
.
Therapeutic Advances in Medical Oncology
vol.
11
,
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al.
(
2019
)
.
Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.)
.
Scandinavian Journal of Urology
vol.
53
,
(
1
)
14
-
20
.
de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B
(
2019
)
.
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma
.
European Urology Oncology
Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ et al.
(
2019
)
.
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma
.
European Urology
vol.
75
,
(
1
)
111
-
128
.
Lalani AKA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A
(
2019
)
.
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions
.
European Urology
vol.
75
,
(
1
)
100
-
110
.
Powles T, Rini B
(
2018
)
.
Novel agents and drug development needs in advanced clear cell renal cancer
.
Journal of Clinical Oncology
vol.
36
,
(
36
)
3639
-
3644
.
Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M et al.
(
2018
)
.
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
.
European Urology
vol.
74
,
(
6
)
849
-
851
.
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al.
(
2018
)
.
Erratum to: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (Nature Medicine, (2018), 24, 6, (749-757), 10.1038/s41591-018-0053-3)
.
Nature Medicine
vol.
24
,
(
12
)
Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J et al.
(
2018
)
.
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma
.
Journal of Urology
vol.
200
,
(
6
)
1207
-
1214
.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G et al.
(
2018
)
.
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study
.
European Urology Focus
vol.
4
,
(
6
)
937
-
945
.
Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al.
(
2018
)
.
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
.
European Urology
vol.
74
,
(
6
)
805
-
809
.
Bex A, Powles T, Haanen J
(
2018
)
.
To the editor
.
New England Journal of Medicine
vol.
379
,
(
19
)
1877
-
1878
.
Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI et al.
(
2018
)
.
Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis [Figure presented]
.
European Urology
vol.
74
,
(
5
)
611
-
620
.
Tshuma N, Glynn N, Evanson J, Powles T, Drake WM
(
2018
)
.
Hypothalamitis and severe hypothalamic dysfunction associated with anti–programmed cell death ligand 1 antibody treatment
.
European Journal of Cancer
vol.
104
,
247
-
249
.
Powles T
(
2018
)
.
Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma
.
European Urology
vol.
74
,
(
5
)
679
-
680
.
Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B et al.
(
2018
)
.
Ultra-Sensitive mutation detection and genome-wide DNA copy number reconstruction by error- corrected circulating tumor DNA sequencing
.
Clinical Chemistry
vol.
64
,
(
11
)
1626
-
1635
.
Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS et al.
(
2018
)
.
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
.
Journal of Experimental Medicine
vol.
215
,
(
11
)
2748
-
2759
.
Castellano D, Duran I, Rodríguez-Vida A, Crabb SJ, van der Heijden MS, Font Pous A, Gravis G, Anido Herranz U et al.
(
2018
)
.
A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)
.
Annals of oncology : official journal of the European Society for Medical Oncology
vol.
29
,
Galsky MD, Banchereau R, Kadel EE, Ramirez-Montagut T, Mariathasan S, Thåström A, Rosenberg J, Powles T et al.
(
2018
)
.
Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)
.
Annals of oncology : official journal of the European Society for Medical Oncology
vol.
29
,
Powles T, Morrison L
(
2018
)
.
Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma
.
Nature Reviews Urology
vol.
15
,
(
10
)
585
-
587
.
Gomez de Liano Lista A, Venugopal B, Fife K, Symeonides S, Vasudev NS, Rudman SM, Vohra S, Khasati L et al.
(
2018
)
.
Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP)
.
Annals of oncology : official journal of the European Society for Medical Oncology
.
vol.
29
,
Rini BI, Tannir NM, Escudier B, McDermott DF, Grimm MO, Porta C, Powles T, Kollmannsberger CK et al.
(
2018
)
.
Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
.
Annals of oncology : official journal of the European Society for Medical Oncology
vol.
29
,
viii309
-
viii310
.
Petrylak DP, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A et al.
(
2018
)
.
EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)
.
Annals of oncology : official journal of the European Society for Medical Oncology
vol.
29
,
Rini BI, Huseni M, Atkins MB, McDermott DF, Powles TB, Escudier B, Banchereau R, Liu LF et al.
(
2018
)
.
Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
.
Annals of oncology : official journal of the European Society for Medical Oncology
.
vol.
29
,
viii724
-
viii725
.
Choueiri TK, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B et al.
(
2018
)
.
PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials
.
Annals of oncology : official journal of the European Society for Medical Oncology
.
vol.
29
,
Collinson F, Brown S, Buckley H, Ainsworth G, Howard H, Poad H, Carr G, Banks RE et al.
(
2018
)
.
PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
.
Annals of oncology : official journal of the European Society for Medical Oncology
vol.
29
,
Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T et al.
(
2018
)
.
Rituximab in the treatment of pembrolizumab-induced myasthenia gravis
.
European Journal of Cancer
vol.
102
,
49
-
51
.
Suarez C, Choueiri TK, McDermott DF, Escudier B, Atkins MB, Powles TB, Rini BI, Motzer RJ et al.
(
2018
)
.
Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151
.
Annals of oncology : official journal of the European Society for Medical Oncology
.
vol.
29
,
McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK, Hammers HJ, Porta C et al.
(
2018
)
.
Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
.
Annals of oncology : official journal of the European Society for Medical Oncology
.
vol.
29
,
Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY et al.
(
2018
)
.
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
.
British Journal of Cancer
vol.
119
,
(
6
)
663
-
669
.
Powles T
(
2018
)
.
Choosing Front-line Treatment for Metastatic Renal Cancer: Which Data Are Meaningful?
.
European Urology
vol.
74
,
(
3
)
322
-
323
.
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM
(
2018
)
.
Role of Checkpoint Inhibition in Localized Bladder Cancer
.
European Urology Oncology
vol.
1
,
(
3
)
190
-
198
.
Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K et al.
(
2018
)
.
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
.
British Journal of Cancer
vol.
119
,
(
2
)
160
-
163
.
Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM et al.
(
2018
)
.
An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment
.
Journal of Clinical Epidemiology
vol.
99
,
75
-
83
.
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al.
(
2018
)
.
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
.
Nature Medicine
vol.
24
,
(
6
)
749
-
757
.
Motzer RJ, Escudier B, Powles T, Scheffold C, Choueiri TK
(
2018
)
.
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
.
British Journal of Cancer
vol.
118
,
(
9
)
1176
-
1178
.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P et al.
(
2018
)
.
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma
.
New England Journal of Medicine
vol.
378
,
(
14
)
1277
-
1290
.
Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC et al.
(
2018
)
.
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators
.
Acta Oncologica
vol.
57
,
(
4
)
491
-
497
.
Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB
(
2018
)
.
Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development
.
Clinical Genitourinary Cancer
vol.
16
,
(
2
)
117
-
129
.
Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW et al.
(
2018
)
.
Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer long-term outcomes from a phase 1 study
.
JAMA Oncology
vol.
4
,
(
4
)
537
-
544
.
Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S et al.
(
2018
)
.
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population
.
Clinical Genitourinary Cancer
vol.
16
,
(
2
)
e483
-
e490
.
Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D et al.
(
2018
)
.
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
.
The Lancet Oncology
vol.
19
,
(
4
)
451
-
460
.
Escudier B, Powles T, Motzer RJ, Olencki T, Frontera OA, Oudard S, Rolland F, Tomczak P et al.
(
2018
)
.
Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial
.
Journal of Clinical Oncology
vol.
36
,
(
8
)
765
-
772
.
Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC et al.
(
2018
)
.
Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial
.
Journal of Clinical Oncology
vol.
36
,
(
8
)
757
-
764
.
Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al.
(
2018
)
.
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
.
European Urology
vol.
73
,
(
3
)
462
-
468
.
Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al.
(
2018
)
.
Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
.
European Urology
vol.
73
,
(
3
)
311
-
315
.
Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM et al.
(
2018
)
.
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
.
The Lancet
vol.
391
,
(
10122
)
748
-
757
.
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H et al.
(
2018
)
.
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
.
Nature
vol.
554
,
(
7693
)
544
-
548
.
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S et al.
(
2018
)
.
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
.
Annals of Oncology
vol.
29
,
(
2
)
361
-
369
.
Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G et al.
(
2018
)
.
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors
.
Clinical Genitourinary Cancer
vol.
16
,
(
1
)
e161
-
e167
.
Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G et al.
(
2018
)
.
ESMO consensus conference on testicular germ cell cancer: Diagnosis, treatment and follow-up
.
Annals of Oncology
vol.
29
,
(
8
)
1658
-
1686
.
Stephen Hodi F, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D et al.
(
2018
)
.
Immune-modified response evaluation criteria in solid tumors (imrecist): Refining guidelines to assess the clinical benefit of cancer immunotherapy
.
Journal of Clinical Oncology
vol.
36
,
(
9
)
850
-
858
.
Bene GD, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al.
(
2018
)
.
Neoadjuvant vs. Adjuvant chemotherapy in muscle invasive bladder cancer (MIBC): Analysis from the RISC database
.
Frontiers in Oncology
vol.
8
,
(
NOV
)
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Edward E K, Koeppen H et al.
(
2017
)
.
TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma
.
Annals of Oncology
vol.
28
,
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S et al.
(
2017
)
.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
.
The Lancet
vol.
390
,
(
10109
)
2266
-
2277
.
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM et al.
(
2017
)
.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
.
The Lancet Oncology
vol.
18
,
(
11
)
1483
-
1492
.
Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT et al.
(
2017
)
.
Practice makes perfect: The rest of the story in testicular cancer as a model curable neoplasm
.
Journal of Clinical Oncology
vol.
35
,
(
31
)
3525
-
3528
.
Powles T, Gómez de Liaño A, Ackerman C
(
2017
)
.
Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?
.
European Urology
vol.
72
,
(
5
)
e137
-
e138
.
Paul J, Kelly C, Stobo J, Powles T
(
2017
)
.
Reply to M. Horiguchi et al
.
Journal of Clinical Oncology
vol.
35
,
(
29
)
Powles T, Smith K, Stenzl A, Bedke J
(
2017
)
.
Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
.
European Urology
vol.
72
,
(
4
)
477
-
481
.
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA et al.
(
2017
)
.
Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer
.
Journal of Clinical Oncology
vol.
35
,
(
26
)
2993
-
3001
.
Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Wong Y-N, Pal SK, De Giorgi U et al.
(
2017
)
.
Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC)
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Choueiri TK, Powles T, Zhang T, Quinn DI, Gschwend JE, Wan SS, Poehlein C
(
2017
)
.
KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC)
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Powles T, Motzer RJ, George DJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Mai TH et al.
(
2017
)
.
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Necchi A, Pond GR, Pal SK, Agarwal N, Bowles D, Plimack E, Yu EY, Ladoire S et al.
(
2017
)
.
Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Grivas P, Plimack E, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn N et al.
(
2017
)
.
Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al.
(
2017
)
.
Pembrolizumab +/- chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Petrylak DP, Chi KN, Drakaki A, Sternberg CN, de Wit R, Nishiyama H, Yu EY, Castellano D et al.
(
2017
)
.
RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Lista AGDL, Necchi A, Lavaud P, Carles Galceran J, Castellano D, Ravaud A, Duran I, van Dijk N et al.
(
2017
)
.
Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Badreldin W, Powles T, Menard L, Ho-Yen C, Kermorgant S
(
2017
)
.
Understanding and targeting Met signalling in bladder cancer
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Wong YNS, Joshi K, Khetrapal P, Ismail M, Linares J, Akarca AU, Reading JL, Furness A et al.
(
2017
)
.
Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC)
.
ANNALS OF ONCOLOGY
.
vol.
28
,
Powles T, O'Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, Lee JL, Ong M et al.
(
2017
)
.
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
.
JAMA Oncol
vol.
3
,
(
9
)
e172411
-
e172411
.
Powles T
(
2017
)
.
Interview with Thomas Powles: The use of durvalumab in urothelial cancer - The latest strides in immuno-oncology
.
Future Oncology
vol.
13
,
(
18
)
1581
-
1583
.
Lubbock ALR, Stewart GD, O'Mahony FC, Laird A, Mullen P, O'Donnell M, Powles T, Harrison DJ et al.
(
2017
)
.
Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: A case study in advanced kidney cancer
.
BMC Medicine
vol.
15
,
(
1
)
Van Neste C, Laird A, O¿Mahony F, Van Criekinge W, Deforce D, Van Nieuwerburgh F, Powles T, Harrison DJ et al.
(
2017
)
.
Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome
.
Cellular Oncology
vol.
40
,
(
3
)
293
-
297
.
Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A et al.
(
2017
)
.
Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer
.
Journal of Clinical Oncology
vol.
35
,
(
16
)
1770
-
1777
.
Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, Bex A
(
2017
)
.
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer
.
Angiogenesis
vol.
20
,
(
2
)
205
-
215
.
Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al.
(
2017
)
.
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma
.
European Urology
vol.
71
,
(
5
)
719
-
722
.
González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M et al.
(
2017
)
.
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer
.
European Urology Focus
vol.
3
,
(
2-3
)
280
-
286
.
Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, Bellmunt J
(
2017
)
.
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy
.
BJU International
.
vol.
119
,
579
-
584
.
Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE et al.
(
2017
)
.
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma
.
European Urology
vol.
71
,
(
3
)
426
-
436
.
Bellmunt J, Powles T, Vogelzang NJ
(
2017
)
.
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
.
Cancer Treatment Reviews
vol.
54
,
58
-
67
.
Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J et al.
(
2017
)
.
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
.
European Urology
vol.
71
,
(
2
)
281
-
289
.
BALKWILL F, Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M et al.
(
2017
)
.
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
.
Journal of Clinical Investigation
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A et al.
(
2017
)
.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
.
The Lancet
vol.
389
,
(
10064
)
67
-
76
.
Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U et al.
(
2017
)
.
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival
.
Cancer Medicine
vol.
6
,
(
1
)
186
-
194
.
Stewart GD, De Santis M, Escudier B, Powles T, Sonpavde G
(
2016
)
.
Immunotherapy for Renal Cancer: Sequencing and Combinations
.
European Urology Focus
vol.
2
,
(
6
)
582
-
588
.
Bex A, Ljungberg B, van Poppel H, Powles T
(
2016
)
.
The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016
.
European Urology
vol.
70
,
(
6
)
901
-
905
.
Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A et al.
(
2016
)
.
Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma
.
BMC Medicine
vol.
14
,
(
1
)
185
-
185
.
Powles THOMAS, Huddart RA, Elliott T, SARKER S-J, Ackerman CHARLOTTE, Jones R, Hussaine S, Crabb S et al.
(
2016
)
.
A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients
.
Journal of Clinical Oncology
Powles T, Grivas P, Aragon-Ching JB, Faroun Y, Kessler ER, Tomita Y, Chakrabarti D, Laliberte RJ et al.
(
2016
)
.
A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
.
Annals of Oncology
vol.
27
,
Bamias A, Tzannis K, Liontos M, Crabb SJ, Harshman L, De Giorgi U, Bellmunt J, Wong YN et al.
(
2016
)
.
Adherence to cisplatin-based regimens prescription in “fit” patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis
.
Annals of Oncology
.
vol.
27
,
Tannir N, Powles T, Motzer RJ, Rolland F, Gravis G, Staehler M, Rink M, Retz M et al.
(
2016
)
.
Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
.
Annals of Oncology
.
vol.
27
,
Loriot Y, Rosenberg JE, Powles TB, Necchi A, Hussain S, Morales R, Retz M, Niegisch G et al.
(
2016
)
.
Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study
.
Annals of Oncology
.
vol.
27
,
Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB
(
2016
)
.
Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: a retrospective chart review in the EU
.
Annals of Oncology
vol.
27
,
Powles TB, Escudier B, de Souza P, Chowdhury S, Pook D, Harmenberg U, Basappa N, Geynisman D et al.
(
2016
)
.
Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
.
Annals of Oncology
.
vol.
27
,
Hessel C, Mangeshkar M, Motzer RJ, Escudier B, Powles TB, Schwab G, Choueiri TK
(
2016
)
.
Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
.
Annals of Oncology
.
vol.
27
,
Bamias A, Tzannis K, Liontos M, Harshman L, Crabb SJ, Wong YN, Pal SK, Powles TB et al.
(
2016
)
.
Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database
.
Annals of Oncology
.
vol.
27
,
Balar A, Bellmunt J, O'Donnell PH, Castellano D, Grivas P, Vuky J, Powles T, Plimack ER et al.
(
2016
)
.
Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
.
Annals of Oncology
.
vol.
27
,
Cella D, Escudier B, Tannir N, Powles T, Donskov F, Peltola K, Schmidinger M, Heng D et al.
(
2016
)
.
Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
.
Annals of Oncology
.
vol.
27
,
Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A et al.
(
2016
)
.
Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus
.
European Urology
vol.
70
,
(
2
)
265
-
280
.
Powles T
(
2016
)
.
Where next in kidney cancer?
.
Annals of Oncology
vol.
27
,
(
8
)
1376
-
1377
.
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F et al.
(
2016
)
.
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
.
The Lancet Oncology
vol.
17
,
(
7
)
917
-
927
.
Feber A, Worth DC, Chakravarthy A, de Winter P, Shah K, Arya M, Saqib M, Nigam R et al.
(
2016
)
.
CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma
.
Cancer Research
vol.
76
,
(
16
)
4720
-
4727
.
Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, Jones R, Chowdhury S et al.
(
2016
)
.
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer
.
JAMA Oncology
vol.
2
,
(
10
)
1303
-
1309
.
Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D et al.
(
2016
)
.
Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma
.
Journal of Clinical Oncology
vol.
34
,
(
14
)
1660
-
1668
.
Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH et al.
(
2016
)
.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
.
The Lancet
vol.
387
,
(
10031
)
1909
-
1920
.
Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E et al.
(
2016
)
.
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
.
Annals of Oncology
vol.
27
,
(
5
)
880
-
886
.
Stewart GD, Powles T, Van Neste C, Meynert A, O'Mahony F, Laird A, Deforce D, Van Nieuwerburgh F et al.
(
2016
)
.
Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer
.
Oncotarget
vol.
7
,
(
18
)
25241
-
25250
.
Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles T
(
2016
)
.
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
.
OncoImmunology
vol.
5
,
(
4
)
Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ et al.
(
2016
)
.
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma
.
Cancer
vol.
122
,
(
7
)
1108
-
1115
.
Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS et al.
(
2016
)
.
HLA-B∗57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer
.
Clinical Cancer Research
vol.
22
,
(
6
)
1371
-
1377
.
McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR et al.
(
2016
)
.
Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study
.
Journal of Clinical Oncology
vol.
34
,
(
8
)
833
-
842
.
Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A et al.
(
2016
)
.
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
.
European Urology
.
vol.
69
,
450
-
456
.
Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A et al.
(
2016
)
.
Brain metastases in patients with germ cell tumors: Prognostic factors and treatment options - An analysis from the Global Germ Cell Cancer Group
.
Journal of Clinical Oncology
vol.
34
,
(
4
)
345
-
351
.
Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hofmann F et al.
(
2016
)
.
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy
.
European Urology
vol.
70
,
(
5
)
705
-
706
.
Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N et al.
(
2016
)
.
Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma
.
Molecular Cancer Therapeutics
vol.
15
,
(
1
)
172
-
183
.
Bex A, Powles T, Karam JA
(
2016
)
.
Role of targeted therapy in combination with surgery in renal cell carcinoma
.
International Journal of Urology
vol.
23
,
(
1
)
5
-
12
.
Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F et al.
(
2016
)
.
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy
.
European Urology
vol.
69
,
(
1
)
4
-
6
.
Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F et al.
(
2015
)
.
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: Results of the DATECAN project
.
Annals of Oncology
vol.
26
,
(
12
)
2392
-
2398
.
Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M et al.
(
2015
)
.
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair
.
Oncogene
vol.
34
,
(
46
)
5699
-
5708
.
Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J et al.
(
2015
)
.
Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials
.
The Lancet
vol.
386
,
(
10001
)
1353
-
1361
.
Kurtoglu M, Davarpanah NN, Qin R, Powles T, Rosenberg JE, Apolo AB
(
2015
)
.
Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma
.
Clinical Genitourinary Cancer
vol.
13
,
(
5
)
410
-
420
.
Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF et al.
(
2015
)
.
Pediatric and adolescent extracranial germ cell tumors: The road to collaboration
.
Journal of Clinical Oncology
vol.
33
,
(
27
)
3018
-
3028
.
Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock ALR, Mackay A, Nanda J, O'Donnell M et al.
(
2015
)
.
Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer
.
Clinical Cancer Research
vol.
21
,
(
18
)
4212
-
4223
.
Rosenberg J, Petrylak D, Abidoye O, Van der Heijden MS, Hofman-Censits J, Necchi A, O'Donnell PH, Balmanoukian A et al.
(
2015
)
.
21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)
.
European Journal of Cancer
.
vol.
51
,
Harshman L, Werner L, Wong YN, Yu E, Alva A, Crabb S, Powles T, Rosenberg J et al.
(
2015
)
.
2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC)
.
European Journal of Cancer
.
vol.
51
,
Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F, Hammers H, Hutson T et al.
(
2015
)
.
4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
.
European Journal of Cancer
.
vol.
51
,
s708
-
s709
.
Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K et al.
(
2015
)
.
Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy
.
EUROPEAN UROLOGY
vol.
69
,
(
4
)
660
-
673
.
Powles T
(
2015
)
.
Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?
.
European Urology
vol.
68
,
(
2
)
280
-
282
.
Feldman DR, Powles T
(
2015
)
.
Salvage high-dose chemotherapy for germ cell tumors
.
Urologic Oncology: Seminars and Original Investigations
vol.
33
,
(
8
)
355
-
362
.
Mulders PF, De Santis M, Powles T, Fizazi K
(
2015
)
.
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
.
Cancer Immunology, Immunotherapy
vol.
64
,
(
6
)
655
-
663
.
Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P et al.
(
2015
)
.
Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients
.
European Journal of Cancer
vol.
51
,
(
10
)
1293
-
1302
.
Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Cruz Zambrano C, Burris HA, Kim JW et al.
(
2015
)
.
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC)
.
Journal of Clinical Oncology
.
vol.
33
,
4501
-
4501
.
Harshman LC, Werner L, Wong Y-N, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE et al.
(
2015
)
.
Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC)
.
Journal of Clinical Oncology
.
vol.
33
,
4524
-
4524
.
De Santis M, Mulders P, Fizazi K, Gray TE, McCoy C, Stubbs A, Powles T
(
2015
)
.
First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC)
.
Journal of Clinical Oncology
.
vol.
33
,
e16015
-
e16015
.
Hussain SA, Jackson R, Shields A, Dickinson L, Cornford P, Jones RJ, Lester JF, Chester JD et al.
(
2015
)
.
Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer
.
Journal of Clinical Oncology
.
vol.
33
,
tps4574
-
tps4574
.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T et al.
(
2015
)
.
EAU guidelines on renal cell carcinoma: 2014 update
.
European Urology
vol.
67
,
(
5
)
913
-
924
.
Powles T
(
2015
)
.
Immunotherapy: The development of immunotherapy in urothelial bladder cancer
.
Nature Reviews Clinical Oncology
vol.
12
,
(
4
)
193
-
194
.
Kim JW, Bellmunt J, Powles T, Loriot Y, Vogelzang NJ, Cruz Zambrano C, Burris HA, Teng S-LM et al.
(
2015
)
.
Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study
.
Journal of Clinical Oncology
.
vol.
33
,
297
-
297
.
Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C et al.
(
2015
)
.
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: Results from COMPARZ, a randomized controlled trial
.
Clinical Cancer Research
vol.
21
,
(
5
)
1071
-
1077
.
Stewart G, Van Neste C, Meynert A, Semple C, O'Mahony F, Laird A, Mackay A, Trooskens G et al.
(
2015
)
.
Effect of sunitinib treatment on mutations and methylation in metastatic renal cancer
.
Journal of Clinical Oncology
.
vol.
33
,
492
-
492
.
Ferguson J, McKibben M, Parker JS, Wallen E, Wood CG, Powles T, Rathmell K
(
2015
)
.
Evaluation of the effects of neoadjuvant pazopanib for renal cell carcinoma on intratumor genetic heterogeneity
.
Journal of Clinical Oncology
.
vol.
33
,
425
-
425
.
Fitzpatrick A, Soosaipillai G, Wilson P, Powles T, Shamash J
(
2015
)
.
High Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma in the VEGF Targeted Era
.
Clinical Oncology
vol.
27
,
(
3
)
e7
-
e8
.
Ramos J, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong Y-N, Bellmunt J, De Giorgi U et al.
(
2015
)
.
Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT)
.
Journal of Clinical Oncology
.
vol.
33
,
318
-
318
.
Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S et al.
(
2015
)
.
Is there an antiandrogen withdrawal syndrome with enzalutamide?
.
BJU International
vol.
115
,
(
3
)
373
-
380
.
Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R et al.
(
2015
)
.
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer
.
Eur Urol
vol.
67
,
(
1
)
100
-
110
.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE et al.
(
2015
)
.
Cabozantinib versus everolimus in advanced renal-cell carcinoma
.
New England Journal of Medicine
vol.
373
,
(
19
)
1814
-
1823
.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T et al.
(
2015
)
.
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
.
Cancer
vol.
121
,
(
15
)
2586
-
2593
.
Gurung PMS, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al.
(
2015
)
.
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer
.
International Journal of Cancer
vol.
136
,
(
3
)
709
-
720
.
Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR et al.
(
2015
)
.
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance
.
Journal of Clinical Oncology
vol.
33
,
(
1
)
51
-
57
.
Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, Sobnack R, Colebrook S et al.
(
2014
)
.
GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study
.
Mol Imaging Biol
vol.
16
,
(
6
)
888
-
895
.
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA et al.
(
2014
)
.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
.
Nature
vol.
515
,
(
7528
)
558
-
562
.
Escudier B, Porta C, Powles T, Eisen T, Sternberg CN, Mehmud F, Cella D
(
2014
)
.
Reply to S. Barni et Al and M. Sun et Al
.
J Clin Oncol
vol.
32
,
(
33
)
3783
-
3784
.
Choueiri TK, Escudier B, Pal SK, Jonasch E, Heng D, Powles T, Arkenau HT, Clark E et al.
(
2014
)
.
395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)
.
European Journal of Cancer
.
vol.
50
,
126
-
127
.
Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock ALR, Nanda J et al.
(
2014
)
.
Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer
.
Eur Urol
vol.
66
,
(
5
)
956
-
963
.
Ghazaly E, Perry J, Kitromilidou C, Powles T, Joel S
(
2014
)
.
Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method
.
J Chromatogr B Analyt Technol Biomed Life Sci
vol.
969
,
213
-
218
.
McDermott DF, Kluger HM, Sosman JA, Infante JR, Soria J-C, Hamid O, Delord J-P, Fasso M et al.
(
2014
)
.
Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC)
.
BJU INTERNATIONAL
.
vol.
114
,
12
-
12
.
Berlato C, Kahn MN, Schioppa T, Thompson R, Maniati E, Canosa M, Kulbe H, Sheldon C et al.
(
2014
)
.
Abstract 1076: Antagonists of the chemokine receptor CCR4 reverse the tumor-promoting microenvironment of renal cancer
.
1076
-
1076
.
Powles T, Hawkins R, Ralph C, Larkin J, Jones RJ, Chowdhury S, Boleti E, Fife K et al.
(
2014
)
.
A Randomised Phase Ii Study of Cediranib with or Without Src Inhibition (Saracatinib) in Metastatic Clear Cell Renal Cancer (Rcc) Patients Resistant to Vegf Targeted Therapy
.
Annals of Oncology
.
vol.
25
,
Powles T, Foreshew S-JS, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L et al.
(
2014
)
.
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer
.
Eur J Cancer
vol.
50
,
(
12
)
2057
-
2064
.
Powles T, Davies R, Rini B
(
2014
)
.
Mammalian target of rapamycin inhibitors: the beginning of the end or the end of the beginning?
.
Eur Urol
vol.
66
,
(
2
)
282
-
283
.
Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME et al.
(
2014
)
.
Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity
.
CLINICAL GENITOURINARY CANCER
vol.
12
,
(
4
)
262
-
269
.
Stewart GD, Harrison DJ, Berney DM, Powles T
(
2014
)
.
The molecular biology of renal cancer: another piece of the puzzle
.
Eur Urol
vol.
66
,
(
1
)
85
-
86
.
Powles T, Oudard S, Escudier BJ, Brown JE, Hawkins RE, Castellano DE, Ravaud A, Staehler MD et al.
(
2014
)
.
A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT)
.
Journal of Clinical Oncology
.
vol.
32
,
4525
-
4525
.
Galsky MD, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Chowdhury S, Powles T, Pal SK et al.
(
2014
)
.
Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC)
.
Journal of Clinical Oncology
.
vol.
32
,
4512
-
4512
.
Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Cruz Zambrano C, Bellmunt J et al.
(
2014
)
.
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC)
.
Journal of Clinical Oncology
.
vol.
32
,
5011
-
5011
.
Beaumont JL, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ, Cella D
(
2014
)
.
Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN)
.
Journal of Clinical Oncology
.
vol.
32
,
4581
-
4581
.
Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U et al.
(
2014
)
.
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
.
J Clin Oncol
vol.
32
,
(
14
)
1412
-
1418
.
Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJG, Powles T
(
2014
)
.
Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations
.
Eur Urol
vol.
65
,
(
4
)
766
-
777
.
Bharwani N, Miquel ME, Powles T, Dilks P, Shawyer A, Sahdev A, Wilson PD, Chowdhury S et al.
(
2014
)
.
Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
.
Br J Cancer
vol.
110
,
(
3
)
616
-
624
.
Fitzpatrick AM, Greenwood M, Foreshew A, Nixon J, Sahdev A, Sarwar N, Lim L, Jones RJ et al.
(
2014
)
.
A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
32
,
Kwan A, Shamash J, Powles T, Ansell W, Chowdhury S, Harland SJ, Lamont A, Wade R et al.
(
2014
)
.
An audit of adjuvant carboplatin in patients with stage I testicular seminoma (Anglian Germ Cell Cancer Group, UK)
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
32
,
Choueiri TK, Figueroa DJ, Liu Y, Gagnon RC, Deen KC, Carpenter C, Bartlett-Pandite AN, De Souza P et al.
(
2014
)
.
Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
32
,
Rodriguez-Vida A, Bianchini D, Hughes S, Lorente D, Crawley D, Van Hemelrijck M, Voskoboynik M, Chau NM et al.
(
2014
)
.
Is there an anti-androgen withdrawal effect with enzalutamide?
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
32
,
Stewart G, Laird A, O'Mahony F, Eory L, Lubbock A, Nanda J, O'Donnell M, Mackay A et al.
(
2014
)
.
The effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
32
,
Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, Staehler M, Powles T et al.
(
2014
)
.
Local treatments for metastases of renal cell carcinoma: A systematic review
.
The Lancet Oncology
vol.
15
,
(
12
)
e549
-
e561
.
Gurung PM, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al.
(
2014
)
.
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer
.
International Journal of Cancer
Patel N, Arya M, Muneer A, Powles T, Sullivan M, Hines J, Kelly J
(
2014
)
.
Molecular aspects of upper tract urothelial carcinoma
.
Urol Oncol
vol.
32
,
(
1
)
28.e11
-
28.e20
.
Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A et al.
(
2013
)
.
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer
.
Clin Cancer Res
vol.
19
,
(
24
)
6924
-
6934
.
Choueiri TK, Escudier B, Powles T, Cella D, Lee Y, Laird DA, Scheffold C, Motzer RJ
(
2013
)
.
A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
.
BJU INTERNATIONAL
.
vol.
112
,
4
-
4
.
Powles T, Kelly J
(
2013
)
.
Innovation: London Cancer-multidisciplinary approach to urological cancer
.
Nat Rev Clin Oncol
vol.
10
,
(
11
)
609
-
610
.
Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P et al.
(
2013
)
.
Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
31
,
(
28
)
3490
-
3493
.
Crusz SM, Tang YZ, Sandev A, Kayani I, Harris L, Beltran L, Peters J, Swanton C et al.
(
2013
)
.
Heterogeneous response and progression patterns of renal cell carcinoma metastases in individual patients reveal intra-tumour heterogeneity of anti-angiogenic drug resistance
.
EUROPEAN JOURNAL OF CANCER
.
vol.
49
,
S641
-
S641
.
Lim L, Mathias J, Lampron M, Fehr M, Gruenwald V, Khan M, Crabb S, Choueiri T et al.
(
2013
)
.
Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy
.
EUROPEAN JOURNAL OF CANCER
.
vol.
49
,
S660
-
S660
.
Hodi FS, Powles T, Cassier P, Kowanetz M, Herbst RS, Soria JC, Mokatrin A, Stroh M et al.
(
2013
)
.
MPDL3280A (anti-PDL1): Clinical activity, safety and biomarkers of an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors
.
EUROPEAN JOURNAL OF CANCER
.
vol.
49
,
S184
-
S184
.
Mulder P, De Santis M, Fizazi K, Whitmore J, Sheikh N, McCoy C, Stubbs A, Powles T
(
2013
)
.
Preliminary product parameters from P11-1, a Phase 2, open-label trial of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer (mCRPC)
.
EUROPEAN JOURNAL OF CANCER
.
vol.
49
,
S696
-
S696
.
Powles T
(
2013
)
.
The mechanism of resistance to targeted therapy
.
EUROPEAN JOURNAL OF CANCER
.
vol.
49
,
S38
-
S38
.
Bhattacharyya M, Powles T, Mutsvangwa K, Wilson P, Oliver T, Shamash J
(
2013
)
.
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder
.
Urol Oncol
vol.
31
,
(
6
)
878
-
882
.
Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart GD, Berney D, Sahdev A et al.
(
2013
)
.
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
.
Ann Oncol
vol.
24
,
(
8
)
2098
-
2103
.
Rini BI, Powles T
(
2013
)
.
Biology and Treatment of Advanced Renal Cell Carcinoma: A Global Perspective
.
SEMINARS IN ONCOLOGY
vol.
40
,
(
4
)
419
-
420
.
Powles T, Bascoul-Mollevi C, Kramar A, Lorch A, Beyer J
(
2013
)
.
Prognostic impact of LDH levels in patients with relapsed/refractory seminoma
.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
vol.
139
,
(
8
)
1311
-
1316
.
Jamal-Hanjani M, Karpathakis A, Kwan A, Mazhar D, Ansell W, Shamash J, Harper P, Rudman S et al.
(
2013
)
.
Bone metastases in germ cell tumours: lessons learnt from a large retrospective study
.
BJU INTERNATIONAL
vol.
112
,
(
2
)
176
-
181
.
Tookman L, Rashid S, Matakidou A, Phillips M, Wilson P, Ansell W, Jamal-Hanjani M, Chowdhury S et al.
(
2013
)
.
Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma
.
Acta Oncol
vol.
52
,
(
5
)
987
-
993
.
Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M et al.
(
2013
)
.
Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer
.
CLINICAL GENITOURINARY CANCER
vol.
11
,
(
2
)
175
-
181
.
Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, McDermott DF, Delord J-P et al.
(
2013
)
.
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC)
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
31
,
Powles T, Sarwar N, Stockdale A, Boleti E, Jones RJ, Protheroe A, Chowdhury S, Peters J et al.
(
2013
)
.
Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
31
,
Galsky MD, Chowdhury S, Bellmunt J, Wong Y-N, Recine F, Pal SK, Moshier EL, Ladoire S et al.
(
2013
)
.
Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC)
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
31
,
Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E et al.
(
2013
)
.
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
.
ANNALS OF ONCOLOGY
vol.
24
,
(
4
)
878
-
888
.
Hardt A, Wilson P, Powles T, Shamash J
(
2013
)
.
The Outcome of Brain Metastases in Patients with Metastatic Germ Cell Tumours - Is Cranial Irradiation Necessary?
.
CLINICAL ONCOLOGY
vol.
25
,
(
4
)
E70
-
E71
.
Pal P, Roy A, Moore G, Muzslay M, Lee E, Alder S, Wilson P, Powles T et al.
(
2013
)
.
Keypad mobile phones are associated with a significant increased risk of microbial contamination compared to touch screen phones
.
Journal of Infection Prevention
vol.
14
,
(
2
)
65
-
68
.
Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb S, Shamash J et al.
(
2013
)
.
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López
.
Eur J Cancer
vol.
49
,
(
4
)
986
-
987
.
Powles T, Sharpe K, Berney D, Kayani I, Doshi R, Stewart GD, Reynolds A, Bex A et al.
(
2013
)
.
Dynamic molecular changes with VEGF targeted therapy in metastatic clear cell renal cancer
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
31
,
Powles T, Bex A
(
2013
)
.
Integration of surgery in metastatic renal cancer
.
Renal Cell Carcinoma: Clinical Management
,
Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A
(
2013
)
.
Probability of Downsizing Primary Tumors of Renal Cell Carcinoma by Targeted Therapies Is Related to Size at Presentation
.
UROLOGY
vol.
81
,
(
1
)
111
-
115
.
Powles T, Crusz SM
(
2013
)
.
Sequencing systemic therapies in advanced RCC: is there a best strategy?
.
Am Soc Clin Oncol Educ Book
Powles T, Kollmannsberger C, Feldman DR
(
2013
)
.
The conundrum of clinical trials in adult germ-cell tumours
.
Lancet Oncol
vol.
14
,
(
1
)
14
-
15
.
O'Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, Eory L, O'Donnell M et al.
(
2013
)
.
The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers
.
Journal of visualized experiments : JoVE
(
71
)
Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D et al.
(
2012
)
.
Contrasting effects of sunitinib within in vivo models of metastasis
.
ANGIOGENESIS
vol.
15
,
(
4
)
623
-
641
.
Powles T, Albers P
(
2012
)
.
Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy
.
Clin Genitourin Cancer
vol.
10
,
(
4
)
213
-
218
.
Lim L, Powles T
(
2012
)
.
The management of low-stage non-seminomatous germ cell tumors
.
Oncology Reviews
vol.
6
,
(
2
)
153
-
157
.
Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J et al.
(
2012
)
.
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer
.
Eur J Cancer
vol.
48
,
(
17
)
3171
-
3176
.
Stewart GD, O'Mahony FC, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick ACP et al.
(
2012
)
.
Proteomic analysis of pre- and postsunitinib treated renal cancer tissue to assess tumour heterogeneity and differential protein expression
.
SCOTTISH MEDICAL JOURNAL
vol.
57
,
(
4
)
245
-
246
.
Powles TB, Jones RJ, Crabb S, Sarker S, Boleti E, Shamash J, Sarwar N, Chowdhury S
(
2012
)
.
A PHASE I DOSE ESCALATION STUDY INVESTIGATING DOVITINIB AND EVEROLMUS IN COMBINATION IN METASTATIC CLEAR CELL RENAL CANCER PATIENTS WHO HAVE PREVIOUSLY FAILED VEGF TARGETED THERAPY
.
ANNALS OF ONCOLOGY
.
vol.
23
,
272
-
272
.
Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP et al.
(
2012
)
.
A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer
.
EUROPEAN UROLOGY
vol.
62
,
(
3
)
523
-
533
.
Powles T, Hutson TE
(
2012
)
.
Difficulty in predicting survival in metastatic renal cancer
.
Lancet Oncol
vol.
13
,
(
9
)
859
-
860
.
Lim FL, Shamash J, Wilson P, Powles T
(
2012
)
.
LIVER TOXICITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH PAZOPANIB THERAPY
.
ANNALS OF ONCOLOGY
.
vol.
23
,
290
-
290
.
Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T et al.
(
2012
)
.
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement
.
MEDICAL ONCOLOGY
vol.
29
,
(
3
)
1896
-
1907
.
Birtle AJ, Lewis R, Chester J, Donovan J, Johnson M, Jones RJ, Kockelbergh R, Powles TB et al.
(
2012
)
.
PERI-OPERATIVE CHEMOTHERAPY OR SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER ( POUT - CRUK/11/027) - A NEW RANDOMISED CONTROLLED TRIAL TO DEFINE STANDARD POST-OPERATIVE MANAGEMENT
.
ANNALS OF ONCOLOGY
.
vol.
23
,
292
-
292
.
Sharpe K, Lu Y, Berney D, Rofe C, Powles T
(
2012
)
.
PRECLINICAL DATA INVESTIGATING THE USE OF SARACATINIB IN RENAL CELL CARCINOMA
.
ANNALS OF ONCOLOGY
.
vol.
23
,
172
-
172
.
Pons Valladares F, Choueiri TK, Hutson TE, Powles TB, Porta C, Bracarda S, Lampron ME, Cerbone L et al.
(
2012
)
.
SEQUENTIAL TARGETED THERAPY FOLLOWING PAZOPANIB (PZ) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CANCER (MRCC): EFFICACY AND TOXICITY
.
ANNALS OF ONCOLOGY
.
vol.
23
,
278
-
278
.
Porta C, Powles T
(
2012
)
.
Sequential therapy in metastatic renal cell carcinoma: what comes next?
.
MEDICAL ONCOLOGY
vol.
29
,
(
3
)
1914
-
1915
.
Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N et al.
(
2012
)
.
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder
.
CANCER
vol.
118
,
(
16
)
3920
-
3927
.
Thillai K, Allan S, Powles T, Rudman S, Chowdhury S
(
2012
)
.
Neoadjuvant and adjuvant treatment of renal cell carcinoma
.
EXPERT REVIEW OF ANTICANCER THERAPY
vol.
12
,
(
6
)
765
-
776
.
Powles T
(
2012
)
.
Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns
.
Clin Genitourin Cancer
vol.
10
,
(
2
)
67
-
68
.
Bex A, Powles T
(
2012
)
.
Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when
.
EXPERT REVIEW OF ANTICANCER THERAPY
vol.
12
,
(
6
)
787
-
797
.
Rashid S, Lim L, Powles T
(
2012
)
.
Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy
.
Curr Treat Options Oncol
vol.
13
,
(
2
)
201
-
211
.
Bex A, Powles T, Blank CU, Chowdhury S, Horenblas S, Peters J, Boleti E, Haanen JBAG
(
2012
)
.
Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC)
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
30
,
Badreldin W, Chowdhury S, Harland SJ, Mazhar D, Powles T, Wilson P, Shamash J
(
2012
)
.
The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
30
,
Shamash J, Jacob J, Agrawal S, Powles T, Mutsvangwa K, Wilson P, Stebbing J
(
2012
)
.
Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study
.
Clin Cancer Res
vol.
18
,
(
8
)
2352
-
2359
.
Kitromilidou C, Ghazaly E, Joel S, Powles T
(
2012
)
.
COMBINING HER1-4 TARGETED THERAPIES AND CHEMOTHERAPY IN BLADDER CANCER
.
ANNALS OF ONCOLOGY
.
vol.
23
,
35
-
35
.
Stewart GD, O'Mahony F, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick A et al.
(
2012
)
.
Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
30
,
(
5
)
Karpathakis A, Jamal-Hanjani M, Kwan A, Mazhar D, Rudman SM, Powles T, Shamash J, Chowdhury S
(
2012
)
.
Testicular germ cell tumors with bony metastases: Diagnosis, management, and outcomes (a case series)
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
30
,
(
5
)
Boleti E, Sarwar N, Jones RR, Chowdhury S, Crabb SJ, Shamash J, Peters J, Oades G et al.
(
2012
)
.
The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
30
,
(
5
)
Doshi R, O'Donnel M, Bex A, Beltran L, Sahdev A, Peters J, Harrison DJ, Stewart GD et al.
(
2012
)
.
Renal Cell Carcinoma before and after Sunitinib Therapy. Morphological and Molecular Changes
.
LABORATORY INVESTIGATION
.
vol.
92
,
201A
-
201A
.
Gurung PMS, Williamson M, West C, Counsell N, Ahmed A, Benthani F, Feber A, Dewinter P et al.
(
2012
)
.
The tumour suppressor gene, AIMP3 sensitises bladder cancer to chemo/radiotherapy in vitro and is a prognostic marker for overall survival in patients treated with radiotherapy for muscle invasive disease
.
EUROPEAN UROLOGY SUPPLEMENTS
vol.
11
,
(
1
)
E669
-
U430
.
Lim L, Powles T
(
2012
)
.
New prognostic models in metastatic renal cancer
.
Translational Andrology and Urology
vol.
1
,
(
3
)
144
-
145
.
Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JSA, Powles T, Peters JL
(
2012
)
.
Performing Cytoreductive Nephrectomy following Targeted Sunitinib Therapy for Metastatic Renal Cell Carcinoma: A Surgical Perspective
.
UROLOGIA INTERNATIONALIS
vol.
89
,
(
1
)
83
-
88
.
Kalin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T et al.
(
2011
)
.
Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome
.
EUR UROL
vol.
60
,
(
6
)
1235
-
1243
.
Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al.
(
2011
)
.
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis
.
BJU INT
vol.
108
,
(
8
)
1279
-
1283
.
Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al.
(
2011
)
.
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis
.
BJU Int
vol.
108
,
(
8
)
1279
-
1283
.
Stephenson AJ, Aprikian AG, Gilligan TD, Oldenburg J, Powles T, Toner GC, Waters WB
(
2011
)
.
Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009
.
UROLOGY
vol.
78
,
(
4
)
S444
-
S455
.
Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P et al.
(
2011
)
.
Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer
.
Clin Cancer Res
vol.
17
,
(
18
)
6021
-
6028
.
Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, White J, Wason J et al.
(
2011
)
.
Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour
.
BRIT J CANCER
vol.
105
,
(
6
)
766
-
772
.
Bex A, Powles T
(
2011
)
.
Reply from Authors re: Simon P. Kim, R. Houston Thompson. Sunitinib Prior to Planned Cytoreductive Nephrectomy: Is This the New Litmus Test for Metastatic Renal Cell Carcinoma? Eur Urol 2011;60:455-6
.
EUR UROL
vol.
60
,
(
3
)
456
-
457
.
Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E et al.
(
2011
)
.
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer
.
Eur Urol
vol.
60
,
(
3
)
448
-
454
.
Bex A, Powles T
(
2011
)
.
Reply to The sequence of cytoreductive nephrectomy: glass half empty or glass half full?
.
ANN ONCOL
vol.
22
,
(
7
)
1691
-
1691
.
Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Flechon A et al.
(
2011
)
.
Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database
.
J CLIN ONCOL
vol.
29
,
(
16
)
2178
-
2184
.
Powles T
(
2011
)
.
Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?
.
Hematol Oncol Clin North Am
vol.
25
,
(
3
)
517
-
viii
.
Lerner SP, Powles T, Hahn NM, Gardner T, Cheng L, Green J, Berney D, Taber D et al.
(
2011
)
.
A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
29
,
(
15
)
Fizazi K, Powles T, George DJ, Poehlein CH
(
2011
)
.
A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
29
,
(
15
)
Chen GJ, Sonpavde G, Vale CL, Fisher D, Powles T, ABCMAC
(
2011
)
.
Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC)
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
29
,
(
15
)
Shamash J, Jacob J, Powles T, Agrawal S, Mutsvangwa K, Saunders N, Wilson P, Stebbing J
(
2011
)
.
Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
29
,
(
15
)
Powles T, Mollevi C, Kramar A, Lorch A, Beyer J, IPFSG
(
2011
)
.
The prognostic significance of LDH levels in patients with relapsed/refractory seminoma and their predictive value of the new international prognostic score
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
29
,
(
15
)
Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N et al.
(
2011
)
.
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
.
Annals of Oncology
vol.
22
,
(
5
)
1041
-
1047
.
Stewart GD, O'Mahony FC, Powles T, Riddick ACP, Harrison DJ, Faratian D
(
2011
)
.
What can molecular pathology contribute to the management of renal cell carcinoma?
.
NAT REV UROL
vol.
8
,
(
5
)
255
-
265
.
Powles T, Chowdhury S, Shamash J, Bazeos A, Gillessen S, Saunders N, Lim L, Sarwar N et al.
(
2011
)
.
Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib
.
Ann Oncol
vol.
22
,
(
4
)
815
-
820
.
Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, Reynolds AR
(
2011
)
.
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
.
Oncogene
vol.
30
,
(
10
)
1183
-
1193
.
Hussain M, Nair R, Bycroft J, Green JSA, Powles T, Peters JL
(
2011
)
.
A COMPARISON OF OPEN RADICAL NEPHRECTOMY COMPLICATION RATES IN PATIENTS TREATED WITH NEOADJUVANT SUNITINIB FOR METASTATIC RENAL CELL CARCINOMA VERSUS NON-METASTATIC RENAL CELL CARCINOMA
.
EUR UROL SUPPL
vol.
10
,
(
2
)
103
-
103
.
Blick C, Hall P, Pwint T, Munro N, Crew J, Powles T, Macaulay VM, Al-Terkait F et al.
(
2011
)
.
Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
29
,
(
7
)
Powles T, Chowdhury S, Avril N, Bomanji J, Shamash J, Sarwar N, Rockall A, Sahdev A et al.
(
2011
)
.
Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
29
,
(
7
)
Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T
(
2011
)
.
Sunitinib and other targeted therapies for renal cell carcinoma
.
Br J Cancer
vol.
104
,
(
5
)
741
-
745
.
Powles T, Blank C, Chowdhury S, Peters J, Haanen J, O'Brien T, Rockall AR, Sahdev AS et al.
(
2011
)
.
THE OUTCOME OF PATIENTS TREATED WITH UPFRONT SUNITINIB PRIOR TO NEPHRECTOMY IN METASTATIC CLEAR CELL RENAL CANCER
.
EUR UROL SUPPL
vol.
10
,
(
2
)
102
-
103
.
Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P et al.
(
2011
)
.
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol
.
BRIT J CANCER
vol.
104
,
(
4
)
620
-
628
.
Feldman DR, Huddart R, Hall E, Beyer J, Powles T
(
2011
)
.
Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial
.
JOURNAL OF CANCER
vol.
2
,
374
-
377
.
Powles T, Chowdhury S, Bower M, Saunders N, Lim L, Shamash J, Sarwar N, Sadev A et al.
(
2011
)
.
The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer
.
UROL INT
vol.
86
,
(
1
)
53
-
59
.
Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, Powles T
(
2010
)
.
A Synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP
.
Molecular Cancer Therapeutics
vol.
9
,
(
12
)
Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T et al.
(
2010
)
.
Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials
.
EUR UROL
vol.
58
,
(
6
)
819
-
828
.
Lorch A, Beyer J, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Flechon A et al.
(
2010
)
.
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy
.
Journal of Clinical Oncology
vol.
28
,
(
33
)
4906
-
4911
.
Gerlinger M, Wilson P, Powles T, Shamash J
(
2010
)
.
Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy
.
Eur J Cancer
vol.
46
,
(
16
)
2913
-
2918
.
Poffiri E, Miscoria M, Lim L, Shamash J, Chowdhury S, Powles T
(
2010
)
.
THE OUTCOME OF PATIENTS WHO FAIL SUNITINIB AND DO NOT HAVE ACCESS TO SUNITINIB THERAPY
.
ANNALS OF ONCOLOGY
.
vol.
21
,
292
-
292
.
Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, Brock C, Abelman W et al.
(
2010
)
.
A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer
.
Cancer
vol.
116
,
(
15
)
3595
-
3602
.
Gillessen S, Powles T, Lim L, Wilson P, Shamash J
(
2010
)
.
Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience
.
Ann Oncol
vol.
21
,
(
8
)
1589
-
1593
.
Matakidou A, Mutsvangwa K, Ansell W, Lim L, Powles TB, Oliver RT, Shamash J
(
2010
)
.
Single-agent carboplatin AUC10 for metastatic seminoma with IGCCCG good prognosis disease; a feasibility study of the Orchid Clinical Trials Group
.
Ann Oncol
vol.
21
,
(
8
)
1730
-
1731
.
Powles T, Jones R, Chowdhury S, Shamash J, Mantle M, Lim L, Hutson T
(
2010
)
.
The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?
.
BJU Int
vol.
106
,
(
4
)
453
-
457
.
Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, Sharp S, Chaplin T et al.
(
2010
)
.
The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers
.
Am J Pathol
vol.
176
,
(
6
)
2607
-
2615
.
Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A
(
2010
)
.
The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers
.
Int J Urol
vol.
17
,
(
6
)
501
-
511
.
Escudier BJ, Cella D, Gschwend JE, Powles T, Sternberg CN, Hodge R, Lau M, Neary M et al.
(
2010
)
.
A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC)
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
28
,
(
15
)
Chowdhury S, O'Brien TS, Sarwar N, Shamash J, McGrath S, Agrawal S, Lim L, Rudman SM et al.
(
2010
)
.
The effect of sunitinib on immune parameters and haemopoetic stem cell markers in patients with untreated cleat cell renal cancer
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
28
,
(
15
)
Powles T, Kayani I, Blank CU, Chowdhury S, Horenblas S, Sarwar N, Nathan PD, Boleti E et al.
(
2010
)
.
The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer
.
Journal of Clinical Oncology
vol.
28
,
(
15_suppl
)
4603
-
4603
.
Bharwani N, Miquel M, Sahdev A, Powles T, Reznek R, Rockall A
(
2010
)
.
Diffusion-Weighted MRI in the Assessment of Tumor Response to Novel Targeted Therapies in Metastatic Renal Cell Carcinoma
.
AMERICAN JOURNAL OF ROENTGENOLOGY
.
vol.
194
,
El-Hariry I, Powles T, Lau MR, Sternberg CN, Ravaud A, von der Maase H, Zantl N, Harper P et al.
(
2010
)
.
Amplification of epidermal growth factor receptor gene in renal cell carcinoma
.
EUR J CANCER
vol.
46
,
(
5
)
859
-
862
.
Chowdhury S, Harper P, Powles T
(
2010
)
.
Castration Refractory Prostate Cancer: Cinderella Finally Comes to the Ball
.
ONKOLOGIE
vol.
33
,
(
12
)
655
-
656
.
Matakidou A, Mutsvangwa K, Ansell W, Powles T, Oliver T, Shamash J
(
2009
)
.
Single-agent Carboplatin AUC10 for Metastatic Seminoma with IGCCCG Good Prognosis Disease; a Feasibility Study of the Orchid Clinical Trials Group
.
CLIN ONCOL-UK
vol.
21
,
(
10
)
800
-
800
.
Perry J, Powles T, Shamash J, Veerupillai A, McGrowder E, Noel E, Lu Y-J, Oliver T et al.
(
2009
)
.
The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines
.
Cancer Chemother Pharmacol
vol.
64
,
(
5
)
925
-
933
.
Murugaesu N, Powles T, Bestwick J, Oliver RTD, Shamash J
(
2009
)
.
Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis
.
Osteoporos Int
vol.
20
,
(
9
)
1627
-
1630
.
Josephs DH, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, Mcdermott DF, Powles T et al.
(
2009
)
.
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
27
,
Hahn NM, Powles T, Sweeney CJ
(
2009
)
.
Development of novel agents for bladder cancer
.
Update on Cancer Therapeutics
vol.
3
,
(
4
)
160
-
169
.
Nathan P, Wagstaff J, Porfiri E, Powles T, Eisen T
(
2009
)
.
UK guidelines for the systemic treatment of renal cell carcinoma
.
BRIT J HOSP MED
vol.
70
,
(
5
)
284
-
286
.
Powles T, Robinson D, Stebbing J, Nelson M, Mandalia S, Moller H, Gazzard B, Bower M
(
2009
)
.
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection
.
HIV MED
vol.
10
,
4
-
4
.
Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M
(
2009
)
.
The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease
.
Ann Oncol
vol.
20
,
(
4
)
775
-
779
.
Gerlinger M, Wilson P, Powles T, Oliver RTD, Shamash J
(
2009
)
.
ESTABLISHED PROGNOSTIC MODELS FAIL TO PREDICT THE OUTCOME OF DOSE DENSE CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT GERM CELL TUMOURS (GCTS)
.
EUR UROL SUPPL
vol.
8
,
(
4
)
358
-
358
.
Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H et al.
(
2009
)
.
Highly Active Antiretroviral Therapy and the Incidence of Non-AIDS-Defining Cancers in People With HIV Infection
.
J CLIN ONCOL
vol.
27
,
(
6
)
884
-
890
.
Stancliffe M, Powles T, Bower M
(
2009
)
.
HIV-related lung cancer in the age of HAART
.
Multidisciplinary Respiratory Medicine
vol.
4
,
(
3
)
225
-
228
.
Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM et al.
(
2009
)
.
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
.
Lung Cancer
vol.
63
,
(
1
)
94
-
97
.
Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M, Gazzard B, Stebbing J
(
2009
)
.
Thyroid dysfunction and relationship to antiretroviral therapy in hiv-positive individuals in the HAART era
.
Journal of Acquired Immune Deficiency Syndromes
vol.
50
,
(
1
)
113
-
114
.
Oliver T, Powles T, Nargund V, Berney D
(
2008
)
.
Spontaneous regression of renal cell carcinoma and the role of prognostic factors
.
Clinical Management of Renal Tumors
,
Jones R, Nelson M, Bower M, Powles T, Mandalia S, Gazzard B, Stebbing J
(
2008
)
.
Triple-class antiretroviral agent resistance in a large cohort: Prevalence and clinical outcomes
.
ARCH INTERN MED
vol.
168
,
(
17
)
1926
-
1927
.
Gaughan EM, Dezube BJ, Aboulafia D, Bower M, Strebbing J, Powles T, Pantanowitz L
(
2008
)
.
Human immunodeficiency virus-associated renal cell carcinoma: A transatlantic case series
.
CLIN GENITOURIN CANC
vol.
6
,
(
2
)
86
-
90
.
Bazoes A, Bower M, Powles T
(
2008
)
.
Smoke and mirrors: HIV-related lung cancer
.
Curr Opin Oncol
vol.
20
,
(
5
)
529
-
533
.
Powles T, McFaul S, Stebbing J, Wilson P, Oliver T, Tranter N, Shamash J
(
2008
)
.
The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
.
Onco Targets Ther
vol.
1
,
35
-
39
.
Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T et al.
(
2008
)
.
British HIV Association guidelines for HIV-associated malignancies 2008
.
HIV MED
vol.
9
,
(
6
)
336
-
388
.
Perry J, Nsubuga E, Joel S, Shamash J, El-Hariry I, Powles T
(
2008
)
.
A synergistic interaction between lapatinib and topoisomerase I inhibitors in cisplatin sensitive and resistant cancer cell lines
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
26
,
(
15
)
Gerlinger M, Wilson P, Powles T, Shamash J
(
2008
)
.
Non-castrate status at the end of chemotherapy for metastatic hormone-resistant prostate cancer (HRPC) correlates with a better overall survival
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
26
,
(
15
)
Bower M, Stebbing J, Tuthill MH, Krell J, Campbell V, Nelson M, Gazzard B, Powles T
(
2008
)
.
Recovery of cellular immunity following chemotherapy for AIDS related non Hodgkin's lymphoma
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
26
,
(
15
)
Bazeos A, Powles T, Stebbing J, Mandalia S, Bower M
(
2008
)
.
The increasing incidence of HIV-associated multicentric Castlemans disease
.
JOURNAL OF CLINICAL ONCOLOGY
vol.
26
,
(
15
)
Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M
(
2008
)
.
Use of antidepressants and risk of cancer in individuals infected with HIV
.
J CLIN ONCOL
vol.
26
,
(
14
)
2305
-
2310
.
Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, Ozzard A, Nelson M et al.
(
2008
)
.
Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma
.
BLOOD
vol.
111
,
(
8
)
3986
-
3990
.
Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP et al.
(
2008
)
.
Novel agents for muscle-invasive and advanced urothelial cancer
.
BJU INT
vol.
101
,
(
8
)
937
-
943
.
Macdonald DC, Nelson M, Bower M, Powles T
(
2008
)
.
Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era
.
WORLD J GASTROENTERO
vol.
14
,
(
11
)
1657
-
1663
.
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al.
(
2008
)
.
European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I
.
EUR UROL
vol.
53
,
(
3
)
478
-
496
.
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Alyaba F, Bamberg M, Bodrogi I et al.
(
2008
)
.
European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II
.
EUR UROL
vol.
53
,
(
3
)
497
-
513
.
Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T
(
2008
)
.
The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis
.
ANN ONCOL
vol.
19
,
(
3
)
443
-
447
.
Stebbing J, Powles T, Bower M
(
2008
)
.
AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count
.
AIDS
vol.
22
,
(
4
)
551
-
552
.
Shamash J, Davies A, Ansell W, Mcfaul S, Wilson P, Oliver T, Powles T
(
2008
)
.
A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
.
BRIT J CANCER
vol.
98
,
(
1
)
22
-
24
.
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al.
(
2008
)
.
Corrigendum to: "European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer
.
European Urology
vol.
54
,
(
2
)
Liu WM, Scott KA, Shamash J, Joel S, Powles TB
(
2008
)
.
Enhancing the in vitro cytotoxic activity of Delta(9)-tetrahydrocannabinol in leukemic cells through a combinatorial approach
.
LEUKEMIA LYMPHOMA
vol.
49
,
(
9
)
1800
-
1809
.
Berney DM, Warren AY, Verma M, Kudahetti S, Robson JM, Williams MW, Neal DE, Powles T et al.
(
2008
)
.
Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over
.
Mod Pathol
vol.
21
,
(
1
)
54
-
59
.
Waters L, Nelson M, Mandalia S, Bower M, Powles T, Gazzard B, Stebbing J
(
2008
)
.
The risks and incidence of K65R and L74V mutations and subsequent virologic responses
.
CLIN INFECT DIS
vol.
46
,
(
1
)
96
-
100
.
Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A et al.
(
2007
)
.
Brief communication: rituximab in HIV-associated multicentric Castleman disease
.
Ann Intern Med
vol.
147
,
(
12
)
836
-
839
.
Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR et al.
(
2007
)
.
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
.
Cancer
vol.
110
,
(
12
)
2628
-
2639
.
Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M
(
2007
)
.
Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease [4]
.
Blood
vol.
110
,
(
12
)
4132
-
4133
.
Davies CL, Chinn R, Nelson M, Rasanesan M, Gazzard B, Powles T, Bower M, Stebbing J
(
2007
)
.
Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan
.
AM J NEURORADIOL
vol.
28
,
(
10
)
1988
-
1990
.
Shamash J, Stebbing J, Powles T
(
2007
)
.
Germ-cell tumors
.
NEW ENGL J MED
vol.
357
,
(
17
)
1771
-
1772
.
Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa K, Wilson P, Asterling S et al.
(
2007
)
.
Erratum: GAMEC - A new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours (British Journal of Cancer (2007) 97, (308-314) DOI: 10.1038/6603865)
.
British Journal of Cancer
vol.
97
,
(
8
)
Young AM, Powles T, Holmes P, Wang J, Nelson M, Anderson J, Bower MD, Brock CS
(
2007
)
.
An HIV-associated mediastinal germ cell tumour complicated by acute myeloid leukaemia
.
Journal of HIV Therapy
vol.
12
,
(
3
)
68
-
71
.
Bazeos A, Powles T, Stebbing J
(
2007
)
.
HIV-associated multicentric Castleman's disease: From case reports to evidence
.
Journal of HIV Therapy
vol.
12
,
(
3
)
61
-
62
.
Walters Z, Shamash J, Powles T
(
2007
)
.
Prostate cancer in HIV-positive individuals: what we know and what we don't
.
J HIV Ther
vol.
12
,
(
3
)
66
-
67
.
Stebbing J, Nathan B, Jones R, McKenna A, Powles T, Bower M, Holmes P, Gazzard B et al.
(
2007
)
.
Virological failure and subsequent resistance profiles in individuals exposed to atazanavir
.
AIDS
vol.
21
,
(
13
)
1826
-
1828
.
Shamash J, Powles T, Ansell W, Stebbing J, Mutsvangwa K, Wilson P, Asterling S, Liu S et al.
(
2007
)
.
GAMEC - a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
.
BRIT J CANCER
vol.
97
,
(
3
)
308
-
314
.
Powles T, Murray I, Brock C, Oliver T, Avril N
(
2007
)
.
Molecular positron emission tomography and PET/CT imaging in urological malignancies
.
Eur Urol
vol.
51
,
(
6
)
1511
-
1520
.
Stebbing J, Sanitt A, Teague A, Powles T, Nelson M, Gazzard B, Bower M
(
2007
)
.
Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma
.
J CLIN ONCOL
vol.
25
,
(
16
)
2230
-
2235
.
Shamash J, Powles T, Mutsvangwa K, Wilson P, Ansell W, Walsh E, Berney D, Stebbing J et al.
(
2007
)
.
A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours
.
ANN ONCOL
vol.
18
,
(
5
)
925
-
930
.
Powles T, Ell PJ
(
2007
)
.
Does PET imaging have a role in renal cancers after all?
.
LANCET ONCOL
vol.
8
,
(
4
)
279
-
281
.
Stebbing J, Powles T
(
2007
)
.
Stress in the workplace amongst medical professionals
.
J POSTGRAD MED
vol.
53
,
(
2
)
83
-
84
.
Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al.
(
2007
)
.
A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia
.
BRIT J CANCER
vol.
96
,
(
5
)
732
-
737
.
Powles T, Perry J, Shamash J, Liu W, Oliver T, Joel S
(
2007
)
.
A comparison of the platinum analogues in bladder cancer cell lines
.
UROL INT
vol.
79
,
(
1
)
67
-
72
.
Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al.
(
2006
)
.
Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours (British Journal of Cancer (2006) 95, (1145-1147) DOI: 10.1038/sj.bjc.6603416)
.
British Journal of Cancer
vol.
95
,
(
12
)
Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al.
(
2006
)
.
The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours
.
Br J Cancer
vol.
95
,
(
9
)
1145
-
1147
.
Powles T, Macdonald D, Nelson M, Stebbing J
(
2006
)
.
Hepatocellular cancer in HIV-infected individuals: tomorrow's problem?
.
EXPERT REV ANTICANC
vol.
6
,
(
11
)
1553
-
1558
.
Powles T, Oliver T, Bower M
(
2006
)
.
Non-AIDS-defining cancers in people with HIV infection: a sleeping giant?
.
J HIV Ther
vol.
11
,
(
3
)
57
-
60
.
Stebbing J, Powles T, Nelson M, Bower M
(
2006
)
.
Significance of variation within HIV, EBV, and KSHV subtypes
.
Journal of the International Association of Physicians in AIDS Care
vol.
5
,
(
3
)
93
-
102
.
Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J
(
2006
)
.
Highly active antiretroviral therapy and human immunodeficiency virus - Associated primary cerebral lymphoma
.
Journal of the National Cancer Institute
vol.
98
,
(
15
)
1088
-
1091
.
Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M
(
2006
)
.
The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
24
,
263S
-
263S
.
Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M
(
2006
)
.
A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy
.
Lancet
vol.
367
,
(
9521
)
1495
-
1502
.
Liu WM, Powles TB
(
2006
)
.
Cannabinoids: Do they have a role in cancer therapy?
.
LETT DRUG DES DISCOV
vol.
3
,
(
2
)
76
-
82
.
Powles T, Savage P, Short D, Young A, Pappin C, Seckl MJ
(
2006
)
.
Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate?
.
BRIT J CANCER
vol.
94
,
(
1
)
51
-
54
.
Liu WM, Baird R, Sarker D, Powles T
(
2005
)
.
Antiapoptotic effect of growth factors in leukemia [1]
.
Journal of Clinical Oncology
vol.
23
,
(
3
)
Bhardwa JM, Powles T, Berney D, Baithun S, Nargund VH, Oliver RTD
(
2005
)
.
Assessing the size and stage of testicular germ cell tumours: 1984-2003
.
BJU Int
vol.
96
,
(
6
)
819
-
821
.
Waterston AM, Gumbrell L, Bratt T, Waller S, Gustav-Aspland J, L'Hermenier C, Bellenger K, Campbell M et al.
(
2005
)
.
Phase I study of TNFα AutoVaccine in Patients with metastatic cancer
.
Cancer Immunology, Immunotherapy
vol.
54
,
(
9
)
848
-
857
.
Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T et al.
(
2005
)
.
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy
.
Annals of Internal Medicine
vol.
143
,
(
4
)
Shamash J, Powles T, Mutsangwa K, Cotton L, Oliver T
(
2005
)
.
A phase II study of irinotecan, paclitaxel and oxaliplatin (IPO) in patients with multiply relapsed germ cell tumours (GCT)
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
23
,
384S
-
384S
.
Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T
(
2005
)
.
The changing presentation of germ cell tumours of the testis between 1983 and 2002
.
BJU INT
vol.
95
,
(
9
)
1197
-
1200
.
Berney DM, Argyle K, Cheang M, Powles T, Oliver RTD
(
2005
)
.
Erythropoietin and erythropoietin receptor expression in renal cell carcinomas
.
JOURNAL OF PATHOLOGY
.
vol.
205
,
14
-
14
.
Bower M, Powles T, Stebbing J, Thirlwell C
(
2005
)
.
Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide [10]
.
Journal of Clinical Oncology
vol.
23
,
(
6
)
1328
-
1329
.
Shamash J, Powles T, Wilson P, Ansell W, Oliver T
(
2005
)
.
Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, cisplatin, and mitomycin chemotherapy
.
J CLIN ONCOL
vol.
23
,
(
6
)
1323
-
1325
.
Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S, Oliver T, Liu WM
(
2005
)
.
Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway
.
Blood
vol.
105
,
(
3
)
1214
-
1221
.
Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, Nelson M, Gazzard B
(
2004
)
.
HIV-associated anal cancer: Has highly active antiretroviral therapy reduced the incidence or improved the outcome?
.
Journal of Acquired Immune Deficiency Syndromes
vol.
37
,
(
5
)
1563
-
1565
.
Marvin V, Stebbing J, Powles T, Bower M
(
2004
)
.
The pharmacogenomics of anti-cancer chemotherapy
.
Minerva Biotecnologica
vol.
16
,
(
3
)
181
-
188
.
Oliver T, Shamash J, Powles T, Somasundram U
(
2004
)
.
20 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Could it have been accelerated by 72 hr PET scan response?
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
22
,
447S
-
447S
.
Powles T, Shamash J, Ong J, MacDonald D, Kyle F, Palmiera C, Moller H, Oliver T
(
2004
)
.
The rising incidence of stage I seminoma; a reflection of earlier diagnosis of germ cell cancer of the testis in last 20 years
.
JOURNAL OF CLINICAL ONCOLOGY
.
vol.
22
,
387S
-
387S
.
Powles T, Bower M, Shamash J, Stebbing J, Ong J, Daugaard G, De Ruiter A, Johnson M et al.
(
2004
)
.
Outcome of patients with HIV-related germ cell tumours: a case-control study
.
BRIT J CANCER
vol.
90
,
(
8
)
1526
-
1530
.
Powles T, Powles J, Nelson M, Sandison A, Peston D, Buchannan J, Mandalia S, Gazzard B et al.
(
2004
)
.
Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus
.
J LARYNGOL OTOL
vol.
118
,
(
3
)
207
-
212
.
Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S
(
2004
)
.
Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity
.
Oncogene
vol.
23
,
(
4
)
981
-
990
.
Powles T, Shamash J, Liu W
(
2004
)
.
Erythropoietin to treat anaemia in patients with head and neck cancer
.
LANCET
vol.
363
,
(
9402
)
82
-
82
.
Kaanders JHAM, Van Der Kogel AJ, Haddad R, Posner M, Leyland-Jones B, Mahmud S, Blumberg N, Heal JM et al.
(
2004
)
.
Erythropoietin to treat anaemia in patients with head and neck cancer [2] (multiple letters)
.
Lancet
vol.
363
,
(
9402
)
78
-
79
.
Powles T, Bower M
(
2004
)
.
HIV and the risk of lung cancer
.
Journal of Clinical Oncology
vol.
22
,
(
7
)
1348
-
1349
.
Stebbing J, Wildfire A, Portsmouth S, Powles T, Thirlwell C, Hewitt P, Nelson M, Patterson S et al.
(
2003
)
.
Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: Clinical and angiogenic correlations
.
Annals of Oncology
vol.
14
,
(
11
)
1660
-
1666
.
Powles T, Nelson M, Bower M
(
2003
)
.
HIV-related lung cancer - A growing concern?
.
International Journal of STD and AIDS
vol.
14
,
(
10
)
647
-
651
.
Powles T, Shamash J, Berney D, Oliver RTD
(
2003
)
.
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
.
BRIT J CANCER
vol.
89
,
(
6
)
1140
-
1141
.
Powles T, Thirwell C, Newsom-Davis T, Nelson M, Shah P, Cox S, Gazzard B, Bower M
(
2003
)
.
Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?
.
British Journal of Cancer
vol.
89
,
(
3
)
457
-
459
.
Powles T, Thirlwell C, Nelson M, Bower M
(
2003
)
.
Immune reconstitution inflammatory syndrome mimicking relapse of AIDS related lymphoma in patients with HIV 1 infection
.
Leukemia and Lymphoma
vol.
44
,
(
8
)
1417
-
1419
.
Powles T, Liu W, Shamash J, Oliver T, Joel S
(
2003
)
.
The effect of recombinant erythropoeitin on renal cancer cell lines and its role in chemosensitivity
.
BRITISH JOURNAL OF CANCER
.
vol.
88
,
S66
-
S66
.
Powles T, Shamash J, Joel S, Oliver T, Liu W
(
2003
)
.
The role of CB1 and CB2 receptors in cannabis induced apoptosis in vitro
.
BRITISH JOURNAL OF CANCER
.
vol.
88
,
S25
-
S25
.
Powles T, Bower M, Daugaard G, Shamash J, De Ruiter A, Johnson M, Fisher M, Anderson J et al.
(
2003
)
.
Multicenter study of human immunodeficiency virus-related germ cell tumors
.
J CLIN ONCOL
vol.
21
,
(
10
)
1922
-
1927
.
Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B
(
2003
)
.
HIV-related lung cancer in the era of highly active antiretroviral therapy
.
AIDS
vol.
17
,
(
3
)
371
-
375
.
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P
(
2003
)
.
Overview of the main outcomes in breast-cancer prevention trials
.
Lancet
vol.
361
,
(
9354
)
296
-
300
.
Powles T, Nelson M, Bower M
(
2003
)
.
HIV-related testicular cancer
.
International Journal of STD and AIDS
vol.
14
,
(
1
)
24
-
27
.
Powles T, Daugaard G, Nelson M, Oliver T, Fisher M, Stebbing J, Johnson M, Gazzard B et al.
(
2002
)
.
Multi-centre cohort study of testicular, cancer in men with HIV
.
BRIT J CANCER
vol.
86
,
S19
-
S19
.
Powles T, Imami N, Nelson M, Gazzard BG, Bower M
(
2002
)
.
Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma
.
AIDS
vol.
16
,
(
4
)
531
-
536
.
Powles T, Bower M, Nelson M, Oliver RTD
(
2002
)
.
HIV related testicular cancer
.
GERM CELL TUMOURS V
.
Editors:
Harden, P, Joffe, JK, Jones, WG
,
51
-
52
.
Powles T, Matthews G, Bower M
(
2000
)
.
AIDS related systemic non-Hodgkin's lymphoma
.
Sexually Transmitted Infections
vol.
76
,
(
5
)
335
-
341
.
Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG
(
2000
)
.
Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy
.
Blood
vol.
96
,
(
8
)
2730
-
2734
.
Powles T, Bower M
(
2000
)
.
HIV-associated Hodgkin's disease
.
International Journal of STD and AIDS
vol.
11
,
(
8
)
492
-
494
.
Gill J, Powles T, Bower M
(
2000
)
.
The molecular genetics of human herpesvirus 8
.
Hospital Medicine
vol.
61
,
(
5
)
306
-
309
.